Future perspectives on neuroendocrine tumors.

Area of Science:

• Oncology
• Gastroenterology
• Endocrinology

Background:

• The incidence and prevalence of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) have significantly increased over the past 30 years.
• Improved diagnostic imaging contributes to incidental findings of asymptomatic GEP-NETs.
• Despite diagnostic advances, patients often face considerable delays in diagnosis and treatment.

Purpose of the Study:

• To review advances and limitations in understanding GEP-NETs.
• To identify factors contributing to diagnostic and treatment delays for GEP-NET patients.
• To discuss targeted therapies and clinical trial outcomes for GEP-NETs.

Main Methods:

• Comprehensive literature review of GEP-NETs.
• Analysis of diagnostic imaging improvements and their impact.
• Evaluation of pathogenesis, molecular biology, classification, and staging.
• Review of clinical trial data for targeted therapies.

Main Results:

• Increased incidence of GEP-NETs partly due to incidental diagnoses.
• Persistent delays in diagnosis despite improved imaging.
• Discussion of current understanding and limitations in GEP-NET management.
• Overview of targeted therapies like RAD001 in advanced GEP-NETs.

Conclusions:

• Addressing diagnostic and treatment delays is crucial for improving GEP-NET patient outcomes.
• Continued research into GEP-NET pathogenesis and biology is needed.
• Optimizing diagnostic pathways and therapeutic strategies can enhance patient care.